The new research reports from Fundamental Markets, available for free download at the links above, examine  Union Pacific Corporation (NYSE:UNP), HCA Holdings, Inc. (NYSE:HCA), PulteGroup, Inc. (NYSE:PHM), Amgen Inc. (NASDAQ:AMGN), Eli Lilly and Company (NYSE:LLY), and The AES Corporation (NYSE:AES) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

For the three months ended September 30, 2017 vs September 30, 2016, Union Pacific reported revenue of $5,408 vs $5,174 (up 4.5%), diluted earnings per share $1.50 vs $1.36 (up 10.3%), and dividends per share $0.605 vs $0.55 (up 10.0%). For the twelve months ended December 31, 2016 vs December 31, 2015, Union Pacific reported revenue of $19,941 vs $21,813 (down 8.6%), diluted earnings per share $5.07 vs $5.49 (down 7.7%), and dividends per share $2.255 vs $2.20 (up 2.5%).

For the three months ended September 30, 2017 vs September 30, 2016, PulteGroup reported revenue of $2,130 vs $1943 (up 9.6%), diluted earnings per share $0.58 vs $0.37 (up 56.8%), and dividends per share $0.09 vs $0.09 (unchanged). For the twelve months ended December 31, 2016 vs December 31, 2015, PulteGroup reported revenue of $7,668 vs $5,982 (up 28.2%), diluted earnings per share $1.75 vs $1.36 (up 28.7%), and dividends per share $0.36 vs $0.33 (up 9.1%).

For the three months ended September 30, 2017 vs September 30, 2016, Amgen reported revenue of $5,773 vs $5,811 (down 0.7%), diluted earnings per share $2.76 vs $2.68 (up 3.0%), and dividends per share $1.15 vs $1.00 (up 15.0%). For the twelve months ended December 31, 2016 vs December 31, 2015, Amgen reported revenue of $22,991 vs $21,662 (up 6.1%), diluted earnings per share $10.24 vs $9.06 (up 13.0%), and dividends per share $4.00 vs $3.16 (up 26.6%).

For the three months ended September 30, 2017 vs September 30, 2016, Eli Lilly reported revenue of $5,658.0 vs $5,191.7 (up 9.0%), diluted earnings per share $0.53 vs $0.73 (down 27.4%), and dividends per share $0.52 vs $0.51 (up 2.0%). For the twelve months ended December 31, 2016 vs December 31, 2015, Eli Lilly reported revenue of $21,222.1 vs $19,958.7 (up 6.3%), diluted earnings per share $2.58 vs $2.26 (up 14.2%), and dividends per share $2.05 vs $2.01 (up 2.0%).

Fundamental Markets serves thousands of members and have provided research through some of the world's leading brokerages for over a decade—and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets' roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.

Fundamental Markets' oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets' roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets' Compliance department by Phone, at +1 667-401-0010, or by E-mail at [email protected].

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.